NCT02113813View on ClinicalTrials.gov

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

PHASE1CompletedINTERVENTIONAL

Enrollment

133

Participants

Timeline

Start Date

April 9, 2014

Primary Completion Date

July 28, 2017

Study Completion Date

February 11, 2019

Conditions

Non-Small-Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor Mutations

Interventions

DRUG

naquotinib

oral

DRUG

midazolam

oral

Trial Locations (12)

10065

Site US10008, New York

19104

Site US10009, Philadelphia

21231

Site US10006, Baltimore

22031

Site US10003, Fairfax

27599

Site US10004, Chapel Hill

37232

Site US10002, Nashville

44106

Site US10005, Cleveland

98104

Site US10007, Seattle

20007-2113

Site US10010, Washington D.C.

02114

Site US10012, Boston

02215

Site US10001, Boston

Site US10011, Boston

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02113813 - A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | Biotech Hunter | Biotech Hunter